Celera Presents Data Validating Its Metastasis Score as a Molecular Prognostic Tool in Breast Cancer

Celera (NYSE:CRA), an Applera Corporation business, announced the presentation of data supporting its multi-gene expression prognostic constellation as a predictor of distant metastasis in Tamoxifen(R)-treated breast cancer patients. The prognostic constellation provided information that is distinct to that predicted by routine clinical assessment tools, such as tumor grade, and can quantify risk for metastasis for variable time periods rather than only categorically for 5 or 10 years. A key finding was the calculation of a Metastasis Score (MS) for breast cancer that predicts a 3.5-fold difference in risk between the 20 percent of women at highest risk and the 20 percent of women at...

Want to see the full article?

• Purchase this article for only $3.00